Cosentyx and Robaxin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cosentyx (secukinumab) and Robaxin (methocarbamol). Common drug interactions include wheezing among females and joint effusion among males.

The phase IV clinical study analyzes what interactions people have when they take Cosentyx and Robaxin. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Cosentyx?

Cosentyx has active ingredients of secukinumab. It is often used in psoriatic arthritis. eHealthMe is studying from 187,247 Cosentyx users. Check the latest studies of Cosentyx.

What is Robaxin?

Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 9,109 Robaxin users. Check the latest studies of Robaxin.



On Jul, 17, 2026

39 people who take Cosentyx and Robaxin together, and have interactions are studied.

Cosentyx and Robaxin drug interactions.

What are the common drug interactions of Cosentyx and Robaxin, by gender? *:

female:

  1. Wheezing (a high-pitched whistling sound made while you breath)
  2. Chest pain
  3. Multiple allergies (allergy to multiple agents)
  4. Pigmentation disorder (disturbances of human skin colour)
  5. Tooth disorder (tooth disease)
  6. Inflammation
  7. Pain of skin
  8. Strangulated hernia (a dangerous condition in which the blood supply to the hernia is cut off)
  9. Aortic aneurysm (enlargement of an aortic artery caused by a weakening of the artery wall)
  10. Aortic valve incompetence

male:

  1. Joint effusion (presence of extra fluid in joint covering)
  2. Skin exfoliation (removal of the oldest dead skin cells)
  3. Arthropathy
  4. Cardiac failure congestive
  5. Depression
  6. Dizziness
  7. Drug ineffective
  8. Dyspnoea (difficult or laboured respiration)
  9. Gait disturbance
  10. General physical health deterioration (weak health status)

What are the common drug interactions of Cosentyx and Robaxin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Arthralgia (joint pain)
  2. Joint swelling
  3. Psoriatic arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop)

40-49:

  1. Fatigue (feeling of tiredness)
  2. Psoriasis (immune-mediated disease that affects the skin)
  3. Psoriatic arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop)
  4. Peripheral swelling
  5. Drug ineffective
  6. Pyrexia (fever)
  7. Abdominal distension
  8. Anosmia (partial or complete loss of the sense of smell)
  9. Arthralgia (joint pain)
  10. Cough

50-59:

  1. Breakthrough pain
  2. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  3. Malaise (a feeling of general discomfort or uneasiness)
  4. Pain
  5. Pharyngitis streptococcal (inflammation of the pharynx caused by infection from. streptococcus)
  6. Upper respiratory tract infection
  7. Wheezing (a high-pitched whistling sound made while you breath)
  8. Strangulated hernia (a dangerous condition in which the blood supply to the hernia is cut off)

60+:

  1. Chest pain
  2. Infection
  3. Fatigue (feeling of tiredness)
  4. Hypoaesthesia (reduced sense of touch or sensation)
  5. Intestinal haemorrhage (bleeding from intestine)
  6. Knee arthroplasty
  7. Neuropathy peripheral (surface nerve damage)
  8. Night sweats (sweating in night)
  9. Pain
  10. Pain in extremity

What are the existing conditions these people have? *

  1. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 14 people, 35.90%
  2. Psoriasis (immune-mediated disease that affects the skin): 9 people, 23.08%
  3. Immunodeficiency Common Variable: 9 people, 23.08%
  4. Ankylosing Spondylitis (type of arthritis affecting the spine): 7 people, 17.95%
  5. Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Cosentyx and Robaxin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cosentyx and Robaxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cosentyx:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Robaxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cosentyx and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Robaxin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on secukinumab and methocarbamol (the active ingredients of Cosentyx and Robaxin, respectively), and Cosentyx and Robaxin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: